Compare Biogen Inc (BIIB) vs Carlyle Group Inc (CG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Carlyle Group Inc — how do they compare? Biogen Inc trades at $206.92 (market cap $30.13B), while Carlyle Group Inc trades at $47.74 (market cap $17.23B). The key difference: Biogen Inc is the larger of the two by market cap, and Carlyle Group Inc pays a 2.9% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| BIIB | CG | |
|---|---|---|
Market Cap | $30.13B | $17.23B |
Sector | Health | Financials |
52-Week High | $216.63 | $69.35 |
52-Week Low | $128.93 | $40.52 |
Enterprise Value | $37.20B | — |
Dividend Yield | — | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $207.13, down 0.39% on the day, with a bullish technical signal and strong analyst support. Recent Q2 2026 earnings of $3.60 per share beat estimates, driven by growth in Alzheimer's and rare disease portfolios, though revenue growth remains modest. The company completed the acquisition of RayThera Inc. in August 2026, enhancing its immunology pipeline. Cash flow from operations remains healthy at $2.20 billion for 2025, supporting strategic investments.
The outlook is positive with a consensus price target of $234.47, implying ~13% upside, but risks include competitive pressures in multiple sclerosis drugs and execution challenges from recent acquisitions. Net income margin compression to 8.32% in 2026 warrants monitoring, though institutional buying and bullish analyst ratings (62.5% Buy) signal confidence in the turnaround story.
CG trades at $47.80, up 0.02% daily, with a bullish technical signal from moving averages and a consensus analyst price target of $59.14. Recent Q2 2026 earnings beat expectations, with EPS of $1.07 versus $0.91 expected, while revenue trends show volatility, declining to $2.8B in 2026 from $3.2B in 2025. The company maintains a dividend of $0.35 per share and has strong institutional interest, with 53.84% of analysts rating it a Buy.
The outlook for CG is positive due to earnings beats and analyst optimism, but risks include inconsistent cash flow from operations and declining revenue. Investment opportunity lies in potential upside to the price target, supported by fundraising strength and strategic partnerships, though investors should monitor execution risks and macroeconomic pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Carlyle Group Inc
The Carlyle Group is one of the world's largest alternative-asset managers, with $376.4 billion in total assets under management, including $259.6 billion in fee-earning AUM, at the end of June 2022. The company has three core business segments: private equity, which includes private equity, real estate, infrastructure and natural resources funds (accounting for 41% of fee-earning AUM and 65% of base management fees during 2021), global credit (45% and 24%) and investment solutions (14% and 11%). The firm primarily serves institutional investors and high-net-worth individuals. Carlyle operates through 29 offices across five continents, serving close to 2,700 active carry fund investors from 95 countries.
Read more on CG →
